China Oncology ›› 2022, Vol. 32 ›› Issue (10): 971-978.doi: 10.19401/j.cnki.1007-3639.2022.10.005
• Article • Previous Articles Next Articles
XU Xiaofei1(), ZHANG Lixia2, DAI Heyang3, CHEN Lingyun1, XUE Jiaojiao1, LI Qingxia1,2()
Received:
2022-06-23
Revised:
2022-10-13
Online:
2022-10-30
Published:
2022-11-29
CLC Number:
XU Xiaofei, ZHANG Lixia, DAI Heyang, CHEN Lingyun, XUE Jiaojiao, LI Qingxia. Value of global longitudinal strain in assessing radiation-induced heart disease in breast cancer: systematic review and meta-analysis[J]. China Oncology, 2022, 32(10): 971-978.
Tab. 1
Characteristics of included studies"
Study | Country | Mean age/year | Patient number | Number of left side n(%) | Chemotherapy n(%) | Targeted therapy n(%) | Radiotherapy dose | Cardioprotective agents n(%) | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Left | Right | Left | Right | ||||||||
Erven[ | Belgium | Left: 54±13 Right: 52±11 | 30 | 20(66.7) | 12(60) | 4(40) | 4(20) | 1(10) | 50 Gy/25 f 16 Gy* | - | |
Erven[ | Belgium | Left: 54±8 Right:52±7 | 75 | 51(68) | 51(100) | 24(100) | 11(22) | 4(17) | 50 Gy/25 f 16 Gy* | - | |
Lo[ | Australia | 60.2±9.1 | 40 | 40(100) | 0(0) | 0(0) | 0(0) | 0(0) | 50 Gy/25 f 42.4 Gy/16 f 10 Gy/16 Gy* | - | |
Tuohinen[ | Finland | Left: 63.6±6.8 Right: 62.9±4.7 | 80 | 60(75) | 0(0) | 0(0) | 0(0) | 0(0) | 50 Gy/25 f 42.56 Gy/16 f 16Gy* | 7(12)a 15(25)b 8(13)c | |
Yu[ | America | 52 | 47 | 26(55.3) | 26(55.3) | 43(91) | 50 Gy/25 f 42.4 Gy/16 f 10 Gy/16 Gy* | 3(6)a 6(13)b | |||
Walker[ | France | 58±9 | 79 | 64(81.0) | 0(0) | 0(0) | 0(0) | 0(0) | 50 Gy/25 f 47 Gy/20 f 9-15 Gy* | - | |
Fourati[ | Tunisia | 50 | 103 | 60(58.3) | portion | 32(31.1) | 50 Gy/25 f 16 Gyf | ||||
Trivedi[ | Australia | 60.2±9.1 | 40 | 40(100) | 0(0) | 0(0) | 50 Gy/25 f 42.4 Gy/16 f 10 Gy/16 Gy* | - | |||
Heggemann[ | Germany | 55 | 49 | 49(100) | 20(40) | 3(6) | 61.29 Gy 52.35 Gy | - |
[1] |
LOIBL S, POORTMANS P, MORROW M, et al. Breast cancer[J]. Lancet, 2021, 397(10286): 1750-1769.
doi: 10.1016/S0140-6736(20)32381-3 pmid: 33812473 |
[2] |
TAYLOR C, CORREA C, DUANE F K, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials[J]. J Clin Oncol, 2017, 35(15): 1641-1649.
doi: 10.1200/JCO.2016.72.0722 pmid: 28319436 |
[3] |
GAASCH A, SCHÖNECKER S, SIMONETTO C, et al. Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks[J]. Radiat Oncol, 2020, 15(1): 117.
doi: 10.1186/s13014-020-01520-8 pmid: 32448164 |
[4] |
ERVEN K, FLORIAN A, SLAGMOLEN P, et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2013, 85(5): 1172-1178.
doi: 10.1016/j.ijrobp.2012.09.022 |
[5] |
TUOHINEN S S, SKYTTÄ T, POUTANEN T, et al. Radiotherapy-induced global and regional differences in early-stage left-sided versus right-sided breast cancer patients: speckle tracking echocardiography study[J]. Int J Cardiovasc Imaging, 2017, 33(4): 463-472.
doi: 10.1007/s10554-016-1021-y pmid: 27873127 |
[6] |
SAWAYA H, SEBAG I A, PLANA J C, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients[J]. Am J Cardiol, 2011, 107(9): 1375-1380.
doi: 10.1016/j.amjcard.2011.01.006 pmid: 21371685 |
[7] |
THAVENDIRANATHAN P, POULIN F, LIM K D, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review[J]. J Am Coll Cardiol, 2014, 63(25): 2751-2768.
doi: 10.1016/j.jacc.2014.01.073 |
[8] |
HEIMDAL A, STØYLEN A, TORP H, et al. Real-time strain rate imaging of the left ventricle by ultrasound[J]. J Am Soc Echocardiogr, 1998, 11(11): 1013-1019.
doi: 10.1016/S0894-7317(98)70151-8 |
[9] |
TRIVEDI S J, CHOUDHARY P, LO Q, et al. Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer[J]. Radiother Oncol, 2019, 132: 148-154.
doi: S0167-8140(18)33547-3 pmid: 30414755 |
[10] |
FOURATI N, CHARFEDDINE S, CHAFFAI I, et al. Subclinical left ventricle impairment following breast cancer radiotherapy: is there an association between segmental doses and segmental strain dysfunction?[J]. Int J Cardiol, 2021, 345: 130-136.
doi: 10.1016/j.ijcard.2021.10.026 pmid: 34687800 |
[11] |
WALKER V, LAIREZ O, FONDARD O, et al. Early detection of subclinical left ventricular dysfunction after breast cancer radiation therapy using speckle-tracking echocardiography: association between cardiac exposure and longitudinal strain reduction (BACCARAT study)[J]. Radiat Oncol, 2019, 14(1): 204.
doi: 10.1186/s13014-019-1408-8 pmid: 31727075 |
[12] |
ERVEN K, JURCUT R, WELTENS C, et al. Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients[J]. Int J Radiat Oncol Biol Phys, 2011, 79(5): 1444-1451.
doi: 10.1016/j.ijrobp.2010.01.004 |
[13] |
LO Q, HEE L A, BATUMALAI V, et al. Subclinical cardiac dysfunction detected by strain imaging during breast irradiation with persistent changes 6 weeks after treatment[J]. Int J Radiat Oncol, 2015, 92(2): 268-276.
doi: 10.1016/j.ijrobp.2014.11.016 pmid: 25968824 |
[14] |
YU A F, HO A Y, BRAUNSTEIN L Z, et al. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy[J]. J Am Soc Echocardiogr, 2019, 32(4): 521-528.
doi: 10.1016/j.echo.2018.12.009 |
[15] |
HEGGEMANN F, GROTZ H, WELZEL G, et al. Cardiac function after multimodal breast cancer therapy assessed with functional magnetic resonance imaging and echocardiography imaging[J]. Int J Radiat Oncol Biol Phys, 2015, 93(4): 836-844.
doi: 10.1016/j.ijrobp.2015.07.2287 |
[16] |
TRAVIS L B, NG A K, ALLAN J M, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy[J]. J Natl Cancer Inst, 2012, 104(5): 357-370.
doi: 10.1093/jnci/djr533 pmid: 22312134 |
[17] |
STEWART F A, HOVING S, RUSSELL N S. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients[J]. Radiat Res, 2010, 174(6): 865-869.
doi: 10.1667/RR1862.1 pmid: 21128810 |
[18] |
SCHULTZ-HECTOR S, TROTT K R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?[J]. Int J Radiat Oncol, 2007, 67(1): 10-18.
doi: 10.1016/j.ijrobp.2006.08.071 |
[19] |
CARDINALE D, SANDRI M T, COLOMBO A, et al. Prognostic value of troponin Ⅰ in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy[J]. Circulation, 2004, 109(22): 2749-2754.
doi: 10.1161/01.CIR.0000130926.51766.CC |
[20] |
GARRONE O, CROSETTO N, LO NIGRO C, et al. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis[J]. Cardiovasc Toxicol, 2012, 12(2): 135-142.
doi: 10.1007/s12012-011-9149-4 pmid: 22189487 |
[21] |
D’ERRICO M P, GRIMALDI L, PETRUZZELLI M F, et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer[J]. Int J Radiat Oncol, 2012, 82(2): e239-e246.
doi: 10.1016/j.ijrobp.2011.03.058 |
[22] |
STOKKE T M, HASSELBERG N E, SMEDSRUD M K, et al. Geometry as a confounder when assessing ventricular systolic function: comparison between ejection fraction and strain[J]. J Am Coll Cardiol, 2017, 70(8): 942-954.
doi: S0735-1097(17)37939-1 pmid: 28818204 |
[23] |
HO E, BROWN A, BARRETT P, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study[J]. Heart, 2010, 96(9): 701-707.
doi: 10.1136/hrt.2009.173997 pmid: 20424152 |
[24] |
HARE J L, BROWN J K, LEANO R, et al. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab[J]. Am Heart J, 2009, 158(2): 294-301.
doi: 10.1016/j.ahj.2009.05.031 pmid: 19619708 |
[1] | ZHANG Jingchen, LI Xin, LI Jiangtao, LI Haiping, CHEN Yanli, NIU Bing, QI Chuanchuan, YE Beibei. LINC02163 targeting miR-338-3p affects proliferation, invasion and migration of breast cancer cells [J]. China Oncology, 2022, 32(9): 818-826. |
[2] | Committee of Breast Cancer Society, Chinese Anti-Cancer Association, Breast Surgeons Committee of Surgeons Branch, Chinese Medical Doctor Association, Committee of Breast Cancer Society, Shanghai Anti-Cancer Association. Expert consensus on oncoplastic surgery of breast tumor and breast reconstruction (2022 edition) [J]. China Oncology, 2022, 32(9): 836-924. |
[3] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[4] | QIU Pengfei, WANG Yongsheng. Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect [J]. China Oncology, 2022, 32(8): 680-687. |
[5] | ZHANG Yu, LIU Qiang. Advances of liquid biopsy in precision treatment of breast cancer [J]. China Oncology, 2022, 32(8): 688-697. |
[6] | ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui. New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising [J]. China Oncology, 2022, 32(8): 698-704. |
[7] | LIU Yiming, FAN Lei, MO Miao, SHAO Zhimin, YU Keda. Factors-associated with short-term effect and long-term survival of ovarian function suppression in estrogen receptor positive breast cancer: a retrospective analysis [J]. China Oncology, 2022, 32(8): 705-711. |
[8] | XIAO Jialong, MO Miao, ZHOU Changming, WANG Zezhou, SHEN Jie, YUAN Jing, YU Keda, LIU Guangyu, WU Jiong, SHEN Zhenzhou, SHAO Zhimin, ZHENG Ying. The effect of the interaction between body mass index and age on the prognosis of breast cancer [J]. China Oncology, 2022, 32(8): 719-726. |
[9] | CHEN Anli, SHEN Haoyuan, YANG Shixiong, DENG Chunyan, HU Chaohua, LIU Hanzhong, WANG Shu, QIAN Fang. Predictive value of plasma long non-coding RNA H19 in neoadjuvant therapy for breast cancer [J]. China Oncology, 2022, 32(8): 727-735. |
[10] | CAI Gang, WANG Shubei, CHEN Jiayi. The current data and challenge of radiotherapy in the case management of gastric cancer [J]. China Oncology, 2022, 32(7): 581-587. |
[11] | LIU Qiang, FANG Yi, WANG Jing. Application progress of single-cell sequencing technology in breast cancer research [J]. China Oncology, 2022, 32(7): 635-642. |
[12] | QIAN Yao, LIU Feng. Research progress and prospects of neoadjuvant endocrine therapy for breast cancer [J]. China Oncology, 2022, 32(7): 643-649. |
[13] | YU Silai, NI Jianjiao, ZHU Zhengfei. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects [J]. China Oncology, 2022, 32(6): 487-498. |
[14] | JIA Xiaoqing, SUN Xiaoyin, JIANG Beiqi, MEI Zhangyi, FU Yun, ZHUANG Zhigang. Neddylation modification regulates lamin B1 expression in breast cancer [J]. China Oncology, 2022, 32(6): 535-541. |
[15] | LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao. Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer [J]. China Oncology, 2022, 32(5): 417-426. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd